Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020236

« Back to Dashboard

NDA 020236 describes SEREVENT, which is a drug marketed by Glaxosmithkline and is included in two NDAs. It is available from two suppliers. Additional details are available on the SEREVENT profile page.

The generic ingredient in SEREVENT is salmeterol xinafoate. There are eighteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the salmeterol xinafoate profile page.

Summary for 020236

Tradename:	SEREVENT
Applicant:	Glaxosmithkline
Ingredient:	salmeterol xinafoate
Patents:	0
Therapeutic Class:	Respiratory Tract Agents
Formulation / Manufacturing:	see details

Medical Subject Heading (MeSH) Categories for 020236

Adrenergic beta-2 Receptor Agonists
Bronchodilator Agents

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	AEROSOL, METERED;INHALATION			Strength	EQ 0.021MG BASE/INH
Approval Date:	Feb 4, 1994	TE:		RLD:	No

Expired US Patents for NDA 020236

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	SEREVENT	salmeterol xinafoate	AEROSOL, METERED;INHALATION	020236-001	Feb 4, 1994	➤ Try a Free Trial	➤ Try a Free Trial
Glaxosmithkline	SEREVENT	salmeterol xinafoate	AEROSOL, METERED;INHALATION	020236-001	Feb 4, 1994	➤ Try a Free Trial	➤ Try a Free Trial
Glaxosmithkline	SEREVENT	salmeterol xinafoate	AEROSOL, METERED;INHALATION	020236-001	Feb 4, 1994	➤ Try a Free Trial	➤ Try a Free Trial
Glaxosmithkline	SEREVENT	salmeterol xinafoate	AEROSOL, METERED;INHALATION	020236-001	Feb 4, 1994	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.